Placental Growth Factor-soluble FMS-like Tyrosine Kinase-1 Ratio in Placenta Accreta Spectrum Disorder: Case Control Study

Sarma Lumbanraja; M. Rizki Yaznil; Andre M. Siahaan; Berry E. P. Bancin; Dizalia Ananda

doi:10.3889/oamjms.2022.8754

Authors

Sarma Lumbanraja Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia
M. Rizki Yaznil Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia
Andre M. Siahaan Department of Neurosurgery, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia
Berry E. P. Bancin Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia https://orcid.org/0000-0002-3147-9857
Dizalia Ananda Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia

DOI:

https://doi.org/10.3889/oamjms.2022.8754

Keywords:

Placenta accreta spectrum disorder, PAS, sFlt-1, PLGF, Ultrasonography

Abstract

AIM: The aim of the study was to assess the ratio of placental growth factor (PLGF)/soluble FMSlike tyrosine kinase (sFLT-1) as a marker for in placenta accreta spectrum disorder stage.

METHODS: We enrolled 50 participants in this study, 25 participants diagnosed with placenta accreta spectrum disorder and 25 participants with normal pregnancy as controls. Diagnosis is based on ultrasonographic criteria from the International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) for spectrum disorders of placenta accreta. Up to 3 cc peripheral venous blood was taken before cesarean section to measured PLGF and sFlt-1 level by ELISA. All data then analyze using SPSS version 26.

RESULTS: In this study, we found that the levels of sFlt-1 in the placenta accreta group (Placenta accreta spectrum stage 0/1/2) were 1711 (136.87) pg/ml, 1474 (122.88) pg/ml, and 1417 (125.45) pg/ml each. This level was higher than the control group of 1246 (98) pg/ml (p = 0.004). In measuring PLGF levels, we found that PLGF levels in the control group were lower than those in the placenta accreta group (PAS 0/1/2) with levels of 404 (33.12) pg/ml, 612 (48.96) pg/ml, 805 (53.48) pg/ml, and 785 (53.64) pg/ml, respectively. We found a correlation between placenta accreta spectrum staging with sFlt-1 levels (r = 0.27 and p = 0.015) and PLGF levels (r = 0.6646 and p = 0.001). Ratio of sFlt-1/PLGF with cutoff point 1.8 has sensitivity 97% and specificity 67% (Area under the curve (AUC) 0.784).

CONCLUSIONS: There is a correlation between sFlt-1 and PLGF levels with placenta accreta staging based on PAS score. sFlt-1/PLGF ratio can be considered as a predictor of placenta accreta to help establish the diagnosis of placenta accreta.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Jauniaux E, Collins S, Burton GJ. Placenta accreta spectrum: Pathophysiology and evidence-based anatomy for prenatal ultrasound imaging. Am J Obstet Gynecol. 2018;218:75-87. https://doi.10.1016/j.ajog.2017.05.067 PMid:28599899 DOI: https://doi.org/10.1016/j.ajog.2017.05.067

Jauniaux E, Bunce C, Grønbeck L, Langhoff-Roos J. Prevalence and main outcomes of placenta accreta spectrum: A systematic review and meta-analysis. Am J Obstet Gynecol. 2019;221:208-18. https://doi.10.1016/j.ajog.2019.01.233 PMid:30716286 DOI: https://doi.org/10.1016/j.ajog.2019.01.233

Miller DA, Chollet JA, Goodwin TM. Clinical risk factors for placenta previa–placenta accreta. Am J Obstet Gynecol. 1997;177:210-4. https://doi.10.1016/s0002-9378(97)70463-0 PMid:9240608 DOI: https://doi.org/10.1016/S0002-9378(97)70463-0

Jauniaux E, Grønbeck L, Bunce C, Langhoff-Roos J, Collins SL. Epidemiology of placenta previa accreta: A systematic review and meta-analysis. BMJ Open. 2019;9:e031193. https://doi.10.1136/bmjopen-2019-031193 PMid:31722942 DOI: https://doi.org/10.1136/bmjopen-2019-031193

Yamashita M, Kumasawa K, Nakamura H, Kimura T. Soluble flt-1 rules placental destiny. Biochem Biophys Res Commun. 2018;496:1243-9. https://doi.10.1016/j.bbrc.2018.01.180 PMid:29409879 DOI: https://doi.org/10.1016/j.bbrc.2018.01.180

De Falco S, Gigante B, Graziella Persico MG. Structure and function of placental growth factor. Trends Cardiovasc Med. 2002;12:241-6. https://doi.10.1016/s1050-1738(02)00168-8 PMid:12242046 DOI: https://doi.org/10.1016/S1050-1738(02)00168-8

Tayade C, Hilchie D, He H, Fang Y, Moons L, Carmeliet P, et al. Genetic deletion of placenta growth factor in mice alters uterine NK cells. J Immunol 2007;178:4267-75. https://doi.10.4049/jimmunol.178.7.4267 PMid:17371983 DOI: https://doi.org/10.4049/jimmunol.178.7.4267

Ultrasoundsupply. Ge Voluson p6 Ultrasound Machine; 2021. Available from: https://www.ultrasoundsupply.com/products/ultrasound-machines/ge-ultrasound/ge-voluson-p6/ [Last accessed 2022 Jan].

Cali G, Forlani F, Lees C, Timor-Tritsch I, Palacios- Jaraquemada J, Dall’Asta A, et al. Prenatal ultrasound staging system for placenta accreta spectrum disorders. Ultrasound Obstetr Gynecol. 2019;53:752-60. https://doi.10.1002/uog.20246 PMid:30834661 DOI: https://doi.org/10.1002/uog.20246

MyBiosource. Sflt-1 Elisa kit: Human Soluble Fmslike Tyrosine Kinase-1 (sFLT-1) Elisa Kit; 2021. Available from: https://www.mybiosource.com/human-elisa-kits/soluble-fms-like-tyrosine-kinase-1-sflt-1/2601616 [Last accessed 2022 Jan].

MyBiosource. Plgf Elisa kit: Human Placental Growth Factor Elisa Kit; 2021. Available from: https://www.mybiosource.com/plgf-human-elisa-kits/placental-growth-factor/761718 [Last accessed 2022 Jan].

IBM. Ibm Spss Statistics 26; 2021. Available from: https://www.ibm.com/support/pages/downloading-ibm-spss-statistics-26 [Last accessed 2022 Jan].

Uyanıkoglu H, Incebıyık A, Turp AB, Çakmak G, Sak S, Hilali NG. Serum angiogenic and anti-angiogenic markers in pregnant women with placenta percreta. Balkan Med J 2018;35:55. https://doi.10.4274/balkanmedj.2016.1890 DOI: https://doi.org/10.4274/balkanmedj.2016.1890

Shainker SA, Dannheim K, Gerson KD, Neo D, Zsengeller ZK, Pernicone E, et al. Down-regulation of soluble fms-like tyrosine kinase 1 expression in invasive placentation. Arch Gynecol Obstet. 2017;296:257-62. https://doi.10.1007/s00404-017-4432-7 PMid:28631072 DOI: https://doi.org/10.1007/s00404-017-4432-7

Tseng JJ, Chou MM. Differential expression of growth-, angiogenesis- and invasion-related factors in the development of placenta accreta. Taiwan J Obstet Gynecol. 2006;45:100-6. https://doi.10.1016/S1028-4559(09)60205-9 PMid:17197348 DOI: https://doi.org/10.1016/S1028-4559(09)60205-9